MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: spasticity"

  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis. Background:…
  • 2017 International Congress

    Efficacy of IncobotulinumtoxinA for the Treatment Of Shoulder Spasticity

    D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon (New York, NY, USA)

    Objective: To evaluate efficacy of botulinum toxin for shoulder spasticity using a post-hoc analysis. Background: Botulinum toxin has been shown to be effective for treating…
  • 2017 International Congress

    Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients

    R. Rosales, K.J. Goh, W. Kumthornthip, M. Mazlan, L. Abdul Latif, M.M. DeLos Santos, C. Chotiyarnwong, P. Tanvijit, J. Balcaitiene, P. Maisonobe, K.-H. Kong (Manila, Philippines)

    Objective: To determine if early post-stroke (within 12 weeks) abobotulinumtoxinA (aboBoNT-A;Dysport®) injections delay appearance or progression of upper limb symptomatic spasticity. Background: Muscle tone changes…
  • 2017 International Congress

    Time to retreatment with botulinum toxin A in upper limb spasticity management: initial data from the Upper Limb International Spasticity (ULIS)-III study

    L. Turner-Stokes, S. Ashford, J. Jacinto, K. Fheodoroff, G. Suarez, P. Maisonobe (London, United Kingdom)

    Objective: The ongoing ULIS-III study aims to describe real-life clinical practice and assess patient‑centered goal attainment with integrated upper limb spasticity (ULS) management that includes…
  • 2017 International Congress

    Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

    R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

    Objective: To identify the epidemiological profile of patients treated with botulinum toxin type A (BTA) in a tertiary clinic in Brazil. Background: BTA is used to…
  • 2016 International Congress

    Quality of life and epidemiological profile of patients undergoing botulinum toxin treatment

    G. Amorelli, L.F. Vasconcellos, M. Spitz, L.F. Fraga (Rio de Janeiro, Brazil)

    Objective: To trace a clinical and epidemiological profile of patients treated with botulinum toxin, evaluating the impact on quality of life. Background: The Botulinum Toxin…
  • 2016 International Congress

    A phase 3, placebo-controlled study with an open-label extension: Sustained incobotulinumtoxinA efficacy in upper-limb post-stroke spasticity over 48 weeks

    P. Kanovský, A. Brashear, E.P. Elovic, M.C. Munin, A. Hanschmann, R. Hiersemenzel, C. Marciniak (Olomouc, Czech Republic)

    Objective: To assess the efficacy and safety of incobotulinumtoxinA for upper-limb post-stroke spasticity. Background: Botulinum toxin injections are a recommended therapy for limb spasticity. We…
  • 2016 International Congress

    Safety and efficacy of escalating doses of incobotulinumtoxinA (400-800U): Increasing improvements in disability due to multifocal upper- and lower-limb spasticity

    J. Wissel, D. Bensmail, B. Rubin, A. Scheschonka, O. Simon, D.M. Simpson (Berlin, Germany)

    Objective: To assess the safety and efficacy of escalating incobotulinumtoxinA doses (400-800U) in patients with spasticity. Background: Botulinum toxin treatment at higher doses than currently…
  • 2016 International Congress

    SPAsticity in PractiCE (SPACE) – An international, observational study of botulinum toxin type A in spasticity

    J. Wissel, J. Harriss, O. Simon, K. Sternberg, N. Roche, C. Cantú-Brito, S. Khatkova, P. Säterö (Berlin, Germany)

    Objective: To collect real-world routine clinical practice data on effectiveness, safety, and quality of life (QoL) for botulinum toxin type A (BoNT-A) treatment of focal…
  • 2016 International Congress

    Botulinum toxin in cerebral palsy children with gait disorder: Different therapy approaches

    G.S. Pilina (Izhevsk, Russia)

    Objective: The purpose of this work was to study the effectiveness of different therapy approaches with Botulinum toxin type A (BTX-A) in Cerebral Palsy (CP)…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7

Most Viewed Abstracts

  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25111 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley